Core Insights - Mural Oncology's lead candidate, nemvaleukin, has shown promising tolerability and anti-tumor activity in the ARTISTRY-1 clinical trial, particularly in platinum-resistant ovarian cancer, which typically does not respond to immunotherapies [1][2][5] Clinical Trial Overview - ARTISTRY-1 was a phase 1/2 trial that evaluated nemvaleukin as both monotherapy and in combination with pembrolizumab, enrolling 286 patients across 32 sites in seven countries from July 2016 to March 2023 [3][5] - The trial demonstrated durable responses in heavily pretreated advanced solid tumors, supporting the foundation for two ongoing potentially registrational trials with data readouts expected in late Q1/early Q2 2025 for PROC and Q2 2025 for mucosal melanoma [4][10] Efficacy Results - Monotherapy with nemvaleukin resulted in a 10% overall response rate (ORR), with confirmed partial responses in melanoma and renal cell carcinoma [6] - Combination therapy with pembrolizumab yielded a 13% ORR, including five confirmed complete responses and 14 confirmed partial responses, with a notable 21% ORR in PROC patients [7] Safety and Tolerability - Nemvaleukin was well tolerated, with a low discontinuation rate of 4% due to adverse events, and the most common severe treatment-related adverse events were neutropenia and anemia [9] Mechanism of Action - Nemvaleukin is an engineered fusion protein designed to enhance the anti-tumor effects of the IL-2 pathway while reducing toxicity, leading to preferential expansion of CD8+ T cells and natural killer cells [11]
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer